Cardiovascular Events Associated with Long-Term Use of Celecoxib, Rofecoxib and Meloxicam in Taiwan
- 1 January 2006
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 29 (3) , 261-272
- https://doi.org/10.2165/00002018-200629030-00009
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritisRheumatology, 2005
- COX-2 Inhibitors — A Lesson in Unexpected ProblemsNew England Journal of Medicine, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial InfarctionAnnals of Internal Medicine, 2005
- Cardiovascular Toxicity of ValdecoxibNew England Journal of Medicine, 2004
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialThe Lancet, 2004
- Cyclooxygenase-2 InhibitorsAnesthesia & Analgesia, 2003
- Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery DiseaseCirculation, 2003
- COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart diseaseThe Lancet, 2002